|
2025 Journal Article Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancerAndreas, V., Faltys, M., Alexander, M., Rogers, J., Parakh, S., Bowyer, S., Warburton, L., Fantoni, A., Clay, T., Arulananda, S., Sullivan, I., Kao, S., Da Silva, I., Brown, L. J., Hughes, B. G.M., Itchins, M., Solomon, B. and John, T. (2025). Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer. Lung Cancer, 209 108786, 108786. doi: 10.1016/j.lungcan.2025.108786 |
|
2025 Journal Article Response-adapted surgical and radiotherapy de-escalation in resectable cutaneous squamous cell cancer using pembrolizumab: the De-Squamate studyLadwa, Rahul, Lee, Jenny H., McGrath, Margaret, Cooper, Caroline, Liu, Howard, Bowman, James, Gupta, Ruta, Cuscaden, Claire, Nottage, Michelle, Clark, Jonathan R., Le, Dieu, Pauley, Marketa, Kulasinghe, Arutha, Gonzalez-Cruz, Jazmina, Porceddu, Sandro V., Hughes, Brett G.M. and Panizza, Benedict (2025). Response-adapted surgical and radiotherapy de-escalation in resectable cutaneous squamous cell cancer using pembrolizumab: the De-Squamate study. Journal of Clinical Oncology, 43 (26) JCO-25-00387, 2888-2896. doi: 10.1200/jco-25-00387 |
|
2025 Journal Article 1657P De-squamate study: Event-free survival outcomes in clinical or pathological complete respondersLadwa, R., Hughes, B.G.M., Panizza, B., Cooper, C., Liu, H., Bowman, J., Gupta, R., Cuscaden, C., Nottage, M.K., Clarke, J., McGrath, M., Porceddu, S.V. and Lee, J. (2025). 1657P De-squamate study: Event-free survival outcomes in clinical or pathological complete responders. Annals of Oncology, 36, S981-S982. doi: 10.1016/j.annonc.2025.08.2285 |
|
2025 Journal Article Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trialDingemans, Anne-Marie C., Syrigos, Konstantinos, Livi, Lorenzo, Paulus, Astrid, Kim, Sang-We, Chen, Yuanbin, Felip, Enriqueta, Griesinger, Frank, Ohashi, Kadoaki, Zalcman, Gerard, Hughes, Brett G.M., Sørensen, Jens Benn, Blais, Normand, Ferreira, Carlos G.M., Lindsay, Colin R., Dziadziuszko, Rafal, Ward, Patrick J., Obiozor, Cynthia Chinedu, Wang, Yang and Peters, Solange (2025). Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial. Lung Cancer, 207 108683, 108683-207. doi: 10.1016/j.lungcan.2025.108683 |
|
2025 Journal Article The development of a high-plex spatial proteomic methodology for the characterisation of the head and neck tumour microenvironmentTan, Chin Wee, Berrell, Naomi, Donovan, Meg L., Monkman, James, Lawler, Clara, Sadeghirad, Habib, Naei, Vahid Yaghoubi, Chen, Jinjin, Rossenbloom, Alyssa, Bonnett, Shilah, Conner, Mark, Filanoski, Brian, Kang, Christine, Beechem, Joseph M., Fraser, John F., Barnett, Catherine, Ladwa, Rahul, Hughes, Brett G. M. and Kulasinghe, Arutha (2025). The development of a high-plex spatial proteomic methodology for the characterisation of the head and neck tumour microenvironment. npj Precision Oncology, 9 (1) 191, 191-1. doi: 10.1038/s41698-025-00963-0 |
|
2025 Journal Article Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerUppaluri, Ravindra, Haddad, Robert I., Tao, Yungan, Le Tourneau, Christophe, Lee, Nancy Y., Westra, William, Chernock, Rebecca, Tahara, Makoto, Harrington, Kevin J., Klochikhin, Arkadiy L., Braña, Irene, Vasconcelos Alves, Gustavo, Hughes, Brett G. M., Oliva, Marc, Pinto Figueiredo Lima, Iane, Ueda, Tsutomu, Rutkowski, Tomasz, Schroeder, Ursula, Mauz, Paul-Stefan, Fuereder, Thorsten, Laban, Simon, Oridate, Nobuhiko, Popovtzer, Aron, Mach, Nicolas, Korobko, Yevhen, Costa, Diogo Alpuim, Hooda-Nehra, Anupama, Rodriguez, Cristina P., Bell, R. Bryan ... Adkins, Douglas (2025). Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. New England Journal of Medicine, 393 (1), 37-50. doi: 10.1056/nejmoa2415434 |
|
2025 Journal Article Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 studyTahara, Makoto, Greil, Richard, Rischin, Danny, Harrington, Kevin J., Burtness, Barbara, de Castro, Gilberto, Psyrri, Amanda, Braña, Irene, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Lin, Jianxin, Gumuscu, Burak, Lerman, Nati and Soulières, Denis (2025). Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. European Journal of Cancer, 221 115395, 115395. doi: 10.1016/j.ejca.2025.115395 |
|
2025 Journal Article Survival after orbital exenteration for primary cutaneous squamous cell carcinoma: a retrospective cohort studyMurray-Douglass, Alexander, Crawford, Lachlan, Hunt, Justin, Dunn, Darryl, Hughes, Brett G. M., Lin, Charles and Fox, Carly (2025). Survival after orbital exenteration for primary cutaneous squamous cell carcinoma: a retrospective cohort study. Annals of Surgical Oncology, 32 (4), 2725-2731. doi: 10.1245/s10434-024-16854-w |
|
2025 Journal Article ASO Visual Abstract: Survival Following Orbital Exenteration for Primary Cutaneous Squamous Cell Carcinoma, a Retrospective Cohort StudyMurray-Douglass, Alexander, Crawford, Lachlan, Hunt, Justin, Dunn, Darryl, Hughes, Brett G. M., Lin, Charles and Fox, Carly (2025). ASO Visual Abstract: Survival Following Orbital Exenteration for Primary Cutaneous Squamous Cell Carcinoma, a Retrospective Cohort Study. Annals of Surgical Oncology, 32 (5), 3485-3486. doi: 10.1245/s10434-025-16995-6 |
|
2025 Journal Article Spatial interaction mapping of PD-1/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy responseNaei, Vahid Yaghoubi, Tubelleza, Rafael, Monkman, James, Sadeghirad, Habib, Donovan, Meg L., Blick, Tony, Wicher, Agata, Bodbin, Sara, Viratham, Amelie, Stad, Robert, Basu, Subham, Cooper, Caroline, Barnett, Catherine, O’Byrne, Ken, Ladwa, Rahul, Warkiani, Majid Ebrahimi, Hughes, Brett G. M. and Kulasinghe, Arutha (2025). Spatial interaction mapping of PD-1/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy response. Journal of Translational Medicine, 23 (1) 177, 1-15. doi: 10.1186/s12967-025-06186-y |
|
2025 Journal Article Durvalumab, tremelimumab, and platinum chemotherapy in EGFR mutation–positive NSCLC: an open-label phase 2 trial (ILLUMINATE)Lee, Chee Khoon, Liao, Bin-Chi, Subramaniam, Shalini, Chiu, Chao-Hua, Mersiades, Antony J., Ho, Chao-Chi, Brown, Chris, Lai, Chun-Liang, Hughes, Brett G. M., Yang, Tsung-Ying, O'Byrne, Ken, Luo, Yung-Hung, Yip, Sonia, Ho, Ching-Liang, Bray, Victoria, Su, Wu-Chou, Moore, Melissa, Feng, Wei-Lien, Bai, Ya-Ying, Ford, Kate, Cummins, Michelle M., Stockler, Martin R., Solomon, Benjamin J., John, Thomas and Chih-Hsin Yang, James (2025). Durvalumab, tremelimumab, and platinum chemotherapy in EGFR mutation–positive NSCLC: an open-label phase 2 trial (ILLUMINATE). JTO Clinical and Research Reports, 6 (2) 100771, 100771. doi: 10.1016/j.jtocrr.2024.100771 |
|
2025 Journal Article Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapyChin, Wee Loong, Cook, Alistair M., Chee, Jonathan, Principe, Nicola, Hoang, Tracy S., Kidman, Joel, Hmon, Khaing P.W., Yeow, Yen, Jones, Matthew E., Hou, Rui, Denisenko, Elena, McDonnell, Alison M., Hon, Chung-Chau, Moody, Jonathan, Anderson, Denise, Yip, Sonia, Cummins, Michelle M., Stockler, Martin R., Kok, Peey-Sei, Brown, Chris, John, Thomas, Kao, Steven C.-H., Karikios, Deme J., O'Byrne, Kenneth J., Hughes, Brett G.M., Lake, Richard A., Forrest, Alistair R.R., Nowak, Anna K., Lassmann, Timo and Lesterhuis, W. Joost (2025). Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy. Cell Reports Medicine, 6 (1) 101882, 1-18. doi: 10.1016/j.xcrm.2024.101882 |
|
2025 Journal Article A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6Hughes, Brett G.M., Guminski, Alexander, Bowyer, Samantha, Migden, Michael R., Schmults, Chrysalyne D., Khushalani, Nikhil I., Chang, Anne Lynn S., Grob, Jean-Jacques, Lewis, Karl D., Ansstas, George, Day, Fiona, Ladwa, Rahul, Stein, Brian N., Muñoz Couselo, Eva, Meier, Friedegund, Hauschild, Axel, Schadendorf, Dirk, Basset-Seguin, Nicole, Modi, Badri, Dalac-Rat, Sophie, Dunn, Lara A., Flatz, Lukas, Mortier, Laurent, Guégan, Sarah, Heinzerling, Lucie M., Mehnert, Janice M., Trabelsi, Sabiha, Soria-Rivas, Ainara, Stratigos, Alexander J. ... Rischin, Danny (2025). A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6. Journal of the American Academy of Dermatology, 92 (1), 68-77. doi: 10.1016/j.jaad.2024.06.108 |
|
2025 Journal Article Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinomaMachiels, J. P., Tao, Y., Licitra, L., Burtness, B., Tahara, M., Rischin, D., Alves, G. V., Lima, I. P.F., Hughes, B. G.M., Pointreau, Y., Aksoy, S., Laban, S., Greil, R., Burian, M., Hetnal, M., Delord, J. P., Mesia, R., Taberna, M., Waldron, J., Simon, C., Gregoire, V., Harrington, K., Black, C. M., Norquist, J. M., Wang, A., Gumuscu, B., Bidadi, B. and Siu, L. L. (2025). Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma. Frontiers in Oncology, 15 1645509, 1645509. doi: 10.3389/fonc.2025.1645509 |
|
2025 Journal Article Type I interferon drives a cellular state inert to TCR-stimulation and could impede effective T-cell differentiation in cancerCorvino, Dillon, Batstone, Martin, Hughes, Brett G. M., Kempchen, Tim, Ng, Susanna S, Salim, Nazhifah, Schneppenheim, Franziska, Rommel, Denise, Kumar, Ananthi, Pearson, Sally, Madore, Jason, Koufariotis, Lambross T., Steinheuer, Lisa Maria, Pathirana, Dilan, Thurley, Kevin, Hölzel, Michael, Borcherding, Nicholas, Braun, Matthias and Bald, Tobias (2025). Type I interferon drives a cellular state inert to TCR-stimulation and could impede effective T-cell differentiation in cancer. European Journal of Immunology, 55 (1) e202451371, 1-13. doi: 10.1002/eji.202451371 |
|
2025 Journal Article Tumour-informed workflow to use ctDNA as a biomarker for risk of recurrence in head and neck cancer patients post-treatmentHuang, Xiaomin, Leo, Paul, Clout, Mhairi, Fink, Lynn, Ellis, Jonathan, Hughes, Brett G. M., Kenny, Lizbeth, Vasani, Sarju and Punyadeera, Chamindie (2025). Tumour-informed workflow to use ctDNA as a biomarker for risk of recurrence in head and neck cancer patients post-treatment. VIEW 20250112. doi: 10.1002/VIW.20250112 |
|
2025 Journal Article Development of a circulating tumour cell culture model from head and neck squamous cell carcinomaHuang, Xiaomin, Zhang, Xi, Weeramange, Chameera Ekanayake, Leo, Paul, Hughes, Brett G. M., Dolcetti, Riccardo, Zeng, Bijun, Mazzieri, Roberta, Hartel, Gunter, Ladwa, Rahul, Taheri, Touraj, Breik, Omar, Kenny, Lizbeth, Vasani, Sarju and Punyadeera, Chamindie (2025). Development of a circulating tumour cell culture model from head and neck squamous cell carcinoma. VIEW 20250085. doi: 10.1002/VIW.20250085 |
|
2024 Journal Article Real‐world outcomes for patients with pleural mesothelioma: a multisite retrospective cohort studyChow, Kar Ven Cavan, Turner, Cassie, Hughes, Brett, Lwin, Zarnie and Chan, Bryan (2024). Real‐world outcomes for patients with pleural mesothelioma: a multisite retrospective cohort study. Asia-Pacific Journal of Clinical Oncology, 20 (6), 723-730. doi: 10.1111/ajco.14098 |
|
2024 Journal Article Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patientsZhang, Xi, Weeramange, Chameera Ekanayake, Hughes, Brett G. M., Vasani, Sarju, Liu, Zhen Yu, Warkiani, Majid, Hartel, Gunter, Ladwa, Rahul, Thiery, Jean Paul, Kenny, Liz, Breik, Omar and Punyadeera, Chamindie (2024). Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients. Cellular and Molecular Life Sciences, 81 (1) 233, 1-14. doi: 10.1007/s00018-024-05269-1 |
|
2024 Journal Article Revalidation of proactive gastrostomy tube placement guidelines for head and neck cancer patients receiving helical intensity-modulated radiotherapyBrown, Teresa E., Byrnes, Angela, Chan, Aaron C., Dwyer, Kathleen, Edwards, Anna, Blake, Claire L., Banks, Merrilyn D., Hughes, Brett G. M., Lin, Charles Y., Kenny, Lizbeth M., Spurgin, Ann-Louise and Bauer, Judith D. (2024). Revalidation of proactive gastrostomy tube placement guidelines for head and neck cancer patients receiving helical intensity-modulated radiotherapy. Current Oncology, 31 (11), 6938-6955. doi: 10.3390/curroncol31110512 |
